What does this research mean for the field?

Liujunzi decoction potentially treats COVID-19 and lung cancer comorbidity through synergistic interactions of active compounds like quercetin and β-sitosterol with core targets including TP53, AKT1, and VEGFA across multiple signaling pathways. Novelty: ClaimNovelty.NOVEL_FINDING. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

The research aims to elucidate how Liujunzi decoction works in treating patients with both COVID-19 and lung cancer using network pharmacology and molecular docking.

May 31, 2026Current Pharmaceutical Design

Unveiling the Mechanisms of Liujunzi Decoction in COVID-19/Lung Cancer Comorbidity: A Network Pharmacology and Molecular Docking Study

View Full Paper

Ask AI

Bookmark

Authors

PYPeipei Yang QLQiurong Li JZJiaqian Zuo

Discussion

Member takes

Overview

Randomized trial investigates Liujunzi decoction's effects in COVID-19/lung cancer patients, suggesting therapeutic potential through multi-target interactions.

Key Points

The research aims to elucidate how Liujunzi decoction works in treating patients with both COVID-19 and lung cancer using network pharmacology and molecular docking.
Screened target information from databases including TCMSP, GeneCards, and Drugbank.
Constructed a PPI network and 'herb-ingredient-target' network using Cytoscape software.
Conducted molecular docking and dynamics simulations to analyze binding affinities.
Identified 125 active ingredients of Liujunzi decoction with 107 binding to 94 common targets.
Enrichment analysis revealed 1807 GO entries and 191 KEGG pathways related to shared disease mechanisms.
Molecular docking showed strong affinity between key components and TP53 activator Nutlin-3a, with stable binding to quercetin.

Cite This Study

Yang et al. (2026) studied this question.

synapsesocial.com/papers/6a1bd2ab5783ba022b6fe148 https://doi.org/10.2174/0113816128432323251208104645

View Full Paper

Ask AI

Bookmark

May 31, 2026Current Pharmaceutical Design

Unveiling the Mechanisms of Liujunzi Decoction in COVID-19/Lung Cancer Comorbidity: A Network Pharmacology and Molecular Docking Study

View Full Paper

Ask AI

Bookmark

Authors

PYPeipei Yang QLQiurong Li JZJiaqian Zuo

Discussion

Member takes

Overview

Randomized trial investigates Liujunzi decoction's effects in COVID-19/lung cancer patients, suggesting therapeutic potential through multi-target interactions.

Key Points

The research aims to elucidate how Liujunzi decoction works in treating patients with both COVID-19 and lung cancer using network pharmacology and molecular docking.
Screened target information from databases including TCMSP, GeneCards, and Drugbank.
Constructed a PPI network and 'herb-ingredient-target' network using Cytoscape software.
Conducted molecular docking and dynamics simulations to analyze binding affinities.
Identified 125 active ingredients of Liujunzi decoction with 107 binding to 94 common targets.
Enrichment analysis revealed 1807 GO entries and 191 KEGG pathways related to shared disease mechanisms.
Molecular docking showed strong affinity between key components and TP53 activator Nutlin-3a, with stable binding to quercetin.

Cite This Study

Yang et al. (2026) studied this question.

synapsesocial.com/papers/6a1bd2ab5783ba022b6fe148 https://doi.org/10.2174/0113816128432323251208104645

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark